Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance
Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance
复制标题
DOI：
10.1038/s41467-020-15684-0
复制
发表时间：
2020-04-20
影响因子：
16.6
通讯作者：
Schrauwen-Hinderling, Vera B.
中科院分区：
文献类型：
--
作者：
Roumans, Kay H. M.;Lindeboom, Lucas;Schrauwen-Hinderling, Vera B.
肝脏脂肪变性与心脏代谢健康不良相关，新生脂肪生成（DNL）导致肝脏脂肪变性和随后的胰岛素抵抗。肝饱和脂肪酸（SFA）可能是DNL的标志物，并被认为是最有害的，有助于胰岛素抵抗。在这里，我们在一项横断面研究设计（ClinicalTrials.gov ID：NCT 03211299）中显示，我们能够使用质子磁共振波谱（H-1-MRS）区分健康和代谢受损志愿者的肝脏SFA、单不饱和脂肪酸和多不饱和脂肪酸的分数。DNL与SFA分数正相关，并且在非酒精性脂肪肝和2型糖尿病患者中升高。有趣的是，SFA分数与肝脏胰岛素敏感性呈强负相关。我们的研究结果表明，肝脂质成分，我们的H-1-MRS方法确定，是DNL的措施，并建议特别是SFA部分可能会妨碍肝脏胰岛素敏感性。肝脏脂肪变性与心脏代谢健康不良相关，新生脂肪生成（DNL）导致肝脏脂肪变性和随后的胰岛素抵抗。在这里，作者使用H-1-MRS方法来显示肝脏SFA分数是DNL的量度，特别是可能妨碍肝脏胰岛素敏感性。
Hepatic steatosis is associated with poor cardiometabolic health, with de novo lipogenesis (DNL) contributing to hepatic steatosis and subsequent insulin resistance. Hepatic saturated fatty acids (SFA) may be a marker of DNL and are suggested to be most detrimental in contributing to insulin resistance. Here, we show in a cross-sectional study design (ClinicalTrials.gov ID: NCT03211299) that we are able to distinguish the fractions of hepatic SFA, mono- and polyunsaturated fatty acids in healthy and metabolically compromised volunteers using proton magnetic resonance spectroscopy (H-1-MRS). DNL is positively associated with SFA fraction and is elevated in patients with non-alcoholic fatty liver and type 2 diabetes. Intriguingly, SFA fraction shows a strong, negative correlation with hepatic insulin sensitivity. Our results show that the hepatic lipid composition, as determined by our H-1-MRS methodology, is a measure of DNL and suggest that specifically the SFA fraction may hamper hepatic insulin sensitivity. Hepatic steatosis is associated with poor cardiometabolic health, with de novo lipogenesis (DNL) contributing to hepatic steatosis and subsequent insulin resistance. Here, the authors use H-1-MRS methodology to show hepatic SFA fraction is a measure of DNL and specifically may hamper hepatic insulin sensitivity.